| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Etrasimod - (CULTIVATE) | Crohn's disease | Phase 2/3 | Oral | Gastroenterology | |
| Pfizer Inc. | Danuglipron (PF-06882961) | Obesity and without type 2 diabetes | Phase 2b | Trial Discontinued | Oral | Endocrinology |
| Pfizer Inc. | Danuglipron (PF-06882961) | Type 2 diabetes mellitus (T2DM) | Phase 2b | Trial Discontinued | Oral | Endocrinology |
| Pfizer Inc. | Vupanorsen (AKCEA-ANGPTL3-LRx) - (TRANSLATE-TIMI 70) | Cardiovascular (CV) risk reduction and hypertriglyceridemia | Phase 2b | Subcutaneous | Cardiology | |
| Pfizer Inc. | Brepocitinib | Systemic lupus erythematosus (SLE) | Phase 2b | Trial Discontinued | Oral | Immunology |
| Pfizer Inc. | RSVpreF (PF-06482077) | RSV-associated lower respiratory tract illness | Phase 2b | Intramuscular | Respiratory | |
| Pfizer Inc. | RIST4721 | Palmoplantar Pustulosis | Phase 2b | Oral | #N/A | |
| Pfizer Inc. | Etrasimod | Eosinophilic esophagitis (EoE) | Phase 2b | Oral | Gastroenterology |